The National Institute for Health and Care Excellence (NICE) is planning to evaluate the pharmaceutical firm Norgine's medical device Endocuff Vision for use in colonoscopy, through its medical technologies evaluation programme.
A Class I sterile medical device, Endocuff Vision is designed to identify pre-cancerous polyps in patients undergoing bowel cancer screening.
Proven to improve the detection of adenomas and polyps when compared to standard colonoscopy, the device can be attached to the end of the colonoscope, which enables better field of view by holding back colonic folds during colonoscope withdrawal.
Norgine UK & ROI general manager Bob Cuffe said: “Norgine is confident that the use of Endocuff Vision brings value to healthcare systems and patients by increasing the detection of cancerous polyps in patients undergoing bowel cancer screening and surveillance.”
It is reported that the identification and elimination of pre-cancerous polyps during colonoscopy minimises the development of and death from colorectal cancer.
Part of Norgine’s colonoscopy portfolio including Klean-Prep and Moviprep, the device is available through Olympus Corporation of the Americas in the US and Canada.
It is also available via the firm's infrastructure in Australia, Austria, Belgium, Finland, France, Denmark, Germany, Italy, Ireland, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland and the UK.
With headquarters in the Netherlands and its global operations in Amsterdam and Harefield, UK, the firm owns a R&D site in Hengoed, Wales, UK and manufacturing sites in Hengoed and in Dreux, France.